Trials / Unknown
UnknownNCT02873390
PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor
A Clinical Study of PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Ningbo Cancer Hospital · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and effectiveness of cell therapy using herinCAR-PD1 cells to treat advanced cancer. Individuals greater than or equal to 18 years of age and less than or equal to 70 years of age who have been diagnosed with relapsed or refractory cancer that has not responded to or has relapsed after standard treatment.
Detailed description
A total of 20 patients may be enrolled over a period of 1-2 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HerinCAR-PD1 cells | herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43. |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2018-03-01
- Completion
- 2018-07-01
- First posted
- 2016-08-19
- Last updated
- 2016-10-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02873390. Inclusion in this directory is not an endorsement.